S. Eder-Lingelbach's Profile

Role	Title	Level	Year	L/R
🐜	Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial 17 auth. Martina Schneider, Marivic Narciso-Abraham, Sandra Hadl, R. McMahon, Sebastian Toepfer, U. Fuchs, R. Hochreiter, A. Bitzer, K. Kosulin, J. Larcher-Senn, ... R. Mader, Katrin L. Dubischar, Oliver Zoihsl, J. Jaramillo, S. Eder-Lingelbach, Vera Buerger, N. Wressnigg	6	2023	6 🐜
🐜	Single-shot live-attenuated chikungunya vaccine in healthy adults: a phase 1, randomised controlled trial. 15 auth. N. Wressnigg, R. Hochreiter, Oliver Zoihsl, Andreas Fritzer, Nicole Bézay, A. Klingler, K. Lingnau, Martina Schneider, U. Lundberg, A. Meinke, ... J. Larcher-Senn, Irena Čorbic-Ramljak, S. Eder-Lingelbach, Katrin L. Dubischar, W. Bender	5	2020	5 🐜
🐜	Efficacy, immunogenicity, and safety of IC43 recombinant Pseudomonas aeruginosa vaccine in mechanically ventilated intensive care patients—a randomized clinical trial 23 auth. C. Adlbrecht, R. Wurm, P. Depuydt, H. Spapen, J. Lorente, T. Staudinger, J. Creteur, C. Zauner, A. Meier‑Hellmann, P. Eller, ... M. Laenen, Z. Molnár, I. Várkonyi, B. Schaaf, M. Héjja, V. Šrámek, H. Schneider, N. Kanesa-Thasan, S. Eder-Lingelbach, A. Klingler, Katrin L. Dubischar, N. Wressnigg, J. Rello	5	2020	5 🐜
🐜	Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial 41 auth. R. Lazarus, B. Querton, Irena Corbic Ramljak, S. Dewasthaly, J. Jaramillo, Katrin L. Dubischar, M. Krammer, P. Weisová, R. Hochreiter, S. Eder-Lingelbach, C. Taucher, A. Finn, C. Bethune, M. Boffito, M. Bula, ... Fiona Burns, R. Clark, Dileep Dasyam, S. Drysdale, S. Faust, E. Gkrania-Klotsas, C. Green, Hanan Hassanin, P. Heath, Amardeep Heer, T. Helliwell, A. Hormis, P. Kalra, R. Lazarus, E. Moran, John Ndikum, I. Page, D. Price, N. Probert, Mahadev Ramjee, T. Rampling, H. Randeva, S. Ryder, J. Steer, E. Thompson, D. Torku	4	2022	4 🐜
🐜	Safety and immunogenicity of the inactivated whole-virus adjuvanted COVID-19 vaccine VLA2001: A randomized, dose escalation, double-blind phase 1/2 clinical trial in healthy adults 26 auth. R. Lazarus, C. Taucher, Claire Brown, Irena Corbic, L. Danon, Katrin L. Dubischar, C. Duncan, S. Eder-Lingelbach, S. Faust, C. Green, Karishma Gokani, R. Hochreiter, J. Wright, Dowan Kwon, A. Middleditch, ... A. Munro, Kush Naker, Florentina Penciu, D. Price, B. Querton, Tawassal Riaz, Amy Ross-Russell, A. Sánchez-González, H. Wardle, Sarah C. Warren, A. Finn	4	2022	4 🐜
🐜	Safety and immunogenicity of an inactivated Vero cell_derived Japanese encephalitis vaccine (IXIARO®, JESPECT®) in a pediatric population in JE non-endemic countries: An uncontrolled, open-label phase 3 study. 14 auth. T. Jelínek, Michael A Cromer, J. Cramer, Deborah J. Mills, Kenneth Lessans, Anthony Gherardin, E. Barnett, Stefan H F Hagmann, H. H. Askling, Sigrid Kiermayr, ... Vera Kadlecek, S. Eder-Lingelbach, C. Taucher, Katrin L. Dubischar	3	2018	3 🐜
🐜	Immunogenicity of the Inactivated Japanese Encephalitis Virus Vaccine IXIARO in Children From a Japanese Encephalitis Virus-endemic Region 9 auth. Katrin L. Dubischar, Vera Kadlecek, B. Sablan, C. Borja-Tabora, S. Gatchalian, S. Eder-Lingelbach, ... Sigrid Kiermayr, M. Spruth, Kerstin Westritschnig	3	2017	3 🐜
🐜	Safety of the Inactivated Japanese Encephalitis Virus Vaccine IXIARO in Children: An Open-label, Randomized, Active-controlled, Phase 3 Study 8 auth. Katrin L. Dubischar, Vera Kadlecek, B. Sablan, C. Borja-Tabora, S. Gatchalian, S. Eder-Lingelbach, ... Zsuzsanna Mueller, Kerstin Westritschnig	3	2017	3 🐜